Research Article

Ming Lei#, Xinghua Du#, Xiaokai Li, Fuke Wang, Ling Gu*, Feng Guo*

**LINC00665 regulates hepatocellular carcinoma by modulating mRNA via the m6A enzyme**

https://doi.org/10.1515/biol-2022-0003
received August 19, 2021; accepted December 12, 2021

Abstract: This study aimed to reveal the mechanism by which long noncoding RNAs (lncRNAs) modulate hepatocellular carcinoma (HCC) by regulating mRNA via the N6-methyladenosine (m6A) enzyme. The expression and clinical data of 365 HCC patients and 50 healthy control samples were downloaded from the Cancer Genome Atlas (TCGA) database. Differentially expressed lncRNAs (DElncRNAs) and differentially expressed mRNAs (DEmRNAs) screened using limma packages from the R. m6A2Target database were used to predict the relationship between m6A lncRNA and m6A enzyme-mRNA. The mRNAs in the lncRNA-m6A enzyme-mRNA network were subjected to enrichment analysis. Cox regression analysis was used to screen for RNAs significantly related to HCC prognosis. The expression of differentially expressed RNAs (DERs) was verified using the TCGA dataset and GSE55092. Eighty-five DElncRNAs and 747 DEmRNAs were identified. The mRNAs in the lncRNA-m6A enzyme-mRNA network were primarily involved in mitotic cell division, the p53 signaling pathway, and the cell cycle. Three lncRNAs and 14 mRNAs were significantly associated with HCC prognosis. Furthermore, the expression of 12 DERs differed significantly between patients in the early and advanced stages. LINC00665 was predicted to regulate 11 mRNAs by modulating IGF2BP1, IGF2BP2, and YTHDF1. Thus, this study provides new insights into the roles of lncRNA and m6A enzymes in HCC.

Keywords: hepatocellular carcinoma, N6-methyladenosine, long noncoding RNA, prognosis, comprehensive network

1 Introduction

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide [1]. HCC usually occurs in the context of chronic liver disease, and its occurrence is related to complex interactions among the host, the disease, and environmental factors. Among them, chronic hepatitis B or C virus infection is the primary risk factor for HCC worldwide [2]. Histological examination of the liver has consistently been used as the gold standard for the diagnosis of HCC. However, the risk of bleeding and tumor cell proliferation during biopsy is an ongoing problem during diagnosis [3]. Statistically, the 5-year survival rate of primary liver cancer in the United States is approximately 16% [4], which is close to that in Europe [5], whereas the survival rate of HCC in underdeveloped areas may be less than 5%. Thus, there is considerable research being undertaken currently on understanding the molecular genetic mechanism underlying HCC to provide a theoretical basis for the diagnosis and treatment of HCC.

N6-methyladenosine (m6A) accounts for approximately 50% of ribonucleotides in mammals [6]. Similar to DNA methylation, epigenetic regulation of m6A modulation is reversible in mammalian cells. The m6A enzymes include “writers,” “erasers,” and “readers,” which can add, remove, or recognize m6A-modified sites, respectively, to alter important biological processes [7]. M6A methylation affects RNA expression, splicing, and translation. Various studies have found that m6A methylation plays a critical role in tumor progression [8]. In addition, abnormal m6A modifications are closely associated with cancer. Researchers have
observed that the methylation of m6A RNA is associated with the self-renewal of glioblastoma stem cells (GSCs), and the presence of GSCs indicates a poor prognosis for glioblastoma multiforme [9]. The m6A methylation enzyme, methyltransferase-like 3 (METTL3), participates in maintaining pluripotency and inhibiting cell differentiation in acute myeloid leukemia by mediating the elevation of m6A [10]. Abnormal upregulation of METTL3 has been identified in patients with HCC, and it often involves the progression of HCC.

Long noncoding RNAs (lncRNAs) are functionally diverse species of noncoding RNA. Studies have demonstrated that lncRNA expression may be closely related to cancer development [11,12]. Several studies have elucidated the regulatory effects of lncRNAs on HCC. Wang et al. reported that lncRNA MCM3AP-AS1 promotes the growth of HCC cells [13], whereas Chen et al. identified that lncRNA CDKN2BAS could predict poor prognosis in patients with HCC and promote metastasis [14]. However, few studies have delineated the exact mechanism by which lncRNAs regulate mRNA expression by modulating m6A regulatory factors.

Based on The Cancer Genome Atlas (TCGA), RNA-seq expression dataset, and m6A enzyme-targeting gene database, this study aimed to reveal how lncRNAs play a role in HCC by regulating m6A regulators to further influence mRNA (Figure S1).

2 Materials and methods

2.1 Data collection and preprocessing

HCC gene expression data were downloaded from the TACG database (https://gdc-portal.nci.nih.gov/) on April 28, 2021. A total of 423 samples were included, comprising 365 tumor samples with clinical information and 50 healthy control samples. The detected lncRNAs and mRNAs were annotated according to the annotation information of the detection platform (Illumina HiSeq 2000 RNA Sequencing, Illumina, Inc., San Diego, California).

2.2 Screening of differentially expressed RNAs (DERs)

Samples were divided into tumor and control groups based on the sample information. DERs between the tumor and control groups were screened using the limma package (version 3.347, Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia) of R3.6.1 [15] with a false discovery rate (FDR) of <0.05, and |log2 fold change| >1 as the threshold for significance. Subsequently, a bidirectional hierarchical clustering based on the centered Pearson correlation algorithm using R3.6.1 pheatmap version 1.2.8 [16] was performed on the expression values of DERs.

2.3 Comprehensive network construction and enrichment analysis

First, the m6A2Target database [17] was used to predict the lncRNAs and mRNAs related to the m6A enzyme. Second, the m6A-related lncRNAs and mRNAs intersected with the significant DERs screened in the previous step. Subsequently, these intersected DERs were selected to construct the differentially expressed lncRNAs (DElncRNAs)-m6A enzyme and differentially expressed mRNAs (DEmRNAs)-m6A enzyme network. After that, the Pearson correlation coefficient (PCC) between the expression levels of significant DElncRNAs and DEmRNAs related to the m6A enzyme was calculated. The DElncRNAs–DEmRNAs coexpression network was constructed with p < 0.05 and |PCC| >0.5. Furthermore, the lncRNAs-m6A enzyme-mRNAs comprehensive network was constructed by combining the DElncRNAs-m6A enzyme and DEmRNAs-m6A enzyme network. All the networks constructed in this study were visualized using Cytoscape (version 3.6.1, National Institute of General Medical Sciences, USA) software (http://www.cytoscape.org/).

Finally, significant DEmRNAs in the comprehensive network underwent gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses using DAVID (version 6.8, Laboratory of Human Retrovirology and Immunoinformatic, USA) [18,19]. Terms with more than two genes enriched and FDR <0.05 were considered to be significantly enriched terms.

2.4 Prognostic correlation analysis of lncRNAs and mRNAs in the comprehensive network

Univariate and multivariate Cox regression analyses in the survival package (version 2.41-1) [20] of R3.6.1 were used to screen for significantly independent prognostic lncRNAs and mRNAs. Based on the median expression level of target lncRNAs and mRNAs, the samples were divided into groups with a high expression level (expression level above or equal to the median expression level)
and low expression level (expression level below the median expression level). The Kaplan–Meier (K–M) curve was used to evaluate the association between target lncRNAs and mRNA expression levels as well as prognosis.

2.5 Expression level analysis of lncRNAs and mRNAs in the comprehensive network in different clinical groups

Independent prognostic clinical factors were screened using univariate and multivariate Cox regression analyses in the survival package (version 2.41-1) of R3.6.1. A log-rank p value less than 0.05 was selected as the threshold for screening independent prognostic clinical factors.

Based on the screened independent prognostic clinical factor information, the samples were divided into different clinical factor feature groups, and the variations in the expression levels of the DERs screened in the previous step were analyzed using the between groups t-test in R3.6.1.

2.6 Verification of the expression of DERs

The expression values of RNAs with significantly different expression levels in different independent prognostic clinical factors screened in the previous step were extracted from the TCGA dataset to analyze the expression differences of these RNAs between tumor samples and normal samples. GSE55092 was subsequently downloaded from the National Center for Biotechnology Information Search database Gene Expression Omnibus database to analyze the expression of DERs. A total of 49 HCC tumor samples and 91 control samples were included in the GSE55092.

3 Results

3.1 Screening of DERs

After annotation, 1,241 lncRNAs and 14,164 mRNAs were identified. A total of 85 DElncRNAs and 747 DEmRNAs were screened between the tumor and control groups (Figure 1a). Thereafter, the upregulated and downregulated top 50 DERs were selected for bidirectional hierarchical clustering according to the ascending power of their log FC values. The heat map obtained has been depicted in Figure 1b, wherein it can be noted that the samples were aggregated in two different directions.

3.2 Comprehensive network construction

m6A enzyme-related lncRNAs were intersected with DElncRNAs, following which 53 DElncRNAs related to m6A enzyme and
12 m6A enzyme enzymes were identified (Figure 2a). This network included 162 connection pairs. Furthermore, a DEmRNAs-m6A enzyme network was also constructed, comprising 127 m6A enzyme-related DEmRNAs and 14 m6A enzyme enzymes (Figure 2b). Subsequently, the IncRNA-mRNA coexpression network containing 53 DEIncRNAs and 127 DEmRNAs was created (Figure 2c). There were 945 significantly correlated connection pairs identified in this coexpression network.

In conjunction with the results of the above analysis, a DEIncRNAs-m6A enzyme-DEmRNAs network was constructed (Figure 2d). Moreover, the enrichment analysis of GO and KEGG signaling pathways was performed on the DEmRNAs that constituted the DEIncRNAs-m6A enzyme-DEmRNAs network. A total of 16 significant GO biological processes and 7 KEGG signaling pathways were screened (Table 1). Enriched biological processes primarily included cell division, proliferation, and mitotic division. Similarly, the KEGG pathways are generally involved in transcriptional misregulation in cancer, the FoxO signaling pathway, the p53 signaling pathway, and cell cycle.

### 3.3 Prognostic correlation analysis

From the DEIncRNAs and DEmRNAs included in the comprehensive network – along with clinical prognosis information of TCGA samples – univariate Cox regression analysis was used to screen the DERs significantly associated with survival prognosis. A total of 83 DERs significantly associated with prognosis were screened, including 7 IncRNAs and 76 mRNAs (Table S1). Multivariate Cox regression analysis was subsequently performed on these 83 DERs for independent prognostic-related DERs. Finally, 17 significantly independent prognosis-related
Deficiency of expression of these DERs resulted in a better prognosis presented in Figure S2. For the validation of the significance of the mRNAs in prognosis, multivariate Cox regression analysis revealed that the low expression of these mRNAs was significantly associated with prognosis (p < 0.05; Figure 3). The other results have been presented in Figure S2.

### 3.4 The expression level of DERs in different clinical groups within the integrated network

Univariate and multivariate Cox regression analyses revealed that the pathologic stage was an independent prognostic factor. Table 2 shows the expression levels of DERs in different clinical groups.

| ID        | Type      | Coef       | Hazard ratio | z      | Pr(>|z|) |
|-----------|-----------|------------|--------------|--------|---------|
| SOX9-A51  | lncRNA    | 0.7263754  | 2.0675728    | 3.181  | 0.001466 |
| LINC00665 | lncRNA    | −0.3784111 | 0.6849489    | −1.996 | 0.04588  |
| LINC01134 | lncRNA    | 0.8595095  | 2.362002     | 1.713  | 0.048675 |
| FLVR1     | mRNA      | 1.2167971  | 3.3696102    | 3.769  | 0.000164 |
| DNAJC6    | mRNA      | 1.0555246  | 2.8734821    | 3.623  | 0.000292 |
| SLCA7A    | mRNA      | −1.6519996 | 0.1916663    | −3.529 | 0.000417 |
| ZWINT     | mRNA      | 1.3523435  | 3.8664762    | 2.928  | 0.003416 |
| KIF20A    | mRNA      | 1.5733317  | 4.8226893    | 2.864  | 0.004186 |
| CENPF     | mRNA      | −1.3804044 | 0.2514768    | −2.507 | 0.012171 |
| CCNB1     | mRNA      | −0.9717552 | 0.3784183    | −2.175 | 0.029622 |
| CBJ2     | mRNA      | 0.4877579  | 1.6286604    | 2.122  | 0.03384  |
| NQO1      | mRNA      | 0.1078229  | 1.1138504    | 2.076  | 0.037923 |
| SFN       | mRNA      | 0.1605477  | 1.1741538    | 2.072  | 0.038287 |
| CCNA2     | mRNA      | 0.4334967  | 1.5426422    | 2.021  | 0.043259 |
| FRAS1     | mRNA      | 0.5390393  | 1.7143591    | 1.994  | 0.046132 |
| SPCC24    | mRNA      | −0.5799142 | 0.5599464    | −1.992 | 0.046388 |
| RECQL4    | mRNA      | −0.6959589 | 0.4985961    | −1.989 | 0.046662 |

### Table 1: GO biological process and KEGG signal pathways in which mRNAs in the comprehensive network are significantly related

| Category       | Term                          | Count | p Value   | FDR   |
|---------------|-------------------------------|-------|-----------|-------|
| Biology process | GO:0007062–sister chromatid cohesion | 12    | $3.35 \times 10^{-11}$ | $1.40 \times 10^{-8}$ |
|               | GO:0007067–cell division       | 18    | $4.06 \times 10^{-11}$ | $1.40 \times 10^{-8}$ |
|               | GO:0007067–mitotic nuclear division | 15    | $3.49 \times 10^{-10}$ | $8.02 \times 10^{-8}$ |
|               | GO:0006260–DNA replication     | 10    | $4.62 \times 10^{-7}$ | $7.97 \times 10^{-5}$ |
|               | GO:0008283–cell proliferation  | 13    | $2.47 \times 10^{-6}$ | $3.41 \times 10^{-4}$ |
|               | GO:0006334–nucleosome assembly | 8     | $8.49 \times 10^{-6}$ | $8.37 \times 10^{-4}$ |
|               | GO:0000086–G2/M transition of mitotic cell cycle | 8 | $2.13 \times 10^{-5}$ | $1.84 \times 10^{-3}$ |
|               | GO:0000082–G1/S transition of mitotic cell cycle | 7 | $3.85 \times 10^{-5}$ | $2.95 \times 10^{-3}$ |
|               | GO:0031145–anaphase-promoting complex-dependent catabolic process | 6 | $1.24 \times 10^{-4}$ | $8.54 \times 10^{-3}$ |
|               | GO:0031577–spindle checkpoint  | 3     | $2.22 \times 10^{-4}$ | $1.39 \times 10^{-2}$ |
|               | GO:0000070–mitotic sister chromatid segregation | 4 | $4.67 \times 10^{-4}$ | $2.48 \times 10^{-2}$ |
|               | GO:0031536–positive regulation of exit from mitosis | 3 | $5.50 \times 10^{-4}$ | $2.71 \times 10^{-2}$ |
|               | GO:0007093–mitotic cell cycle checkpoint | 4 | $9.77 \times 10^{-4}$ | $4.29 \times 10^{-2}$ |
|               | GO:0051726–regulation of cell cycle | 6 | $9.95 \times 10^{-4}$ | $4.29 \times 10^{-2}$ |
|               | GO:1904668–positive regulation of ubiquitin protein ligase activity | 3 | $1.30 \times 10^{-3}$ | $4.74 \times 10^{-2}$ |
|               | GO:0030071–regulation of mitotic metaphase/anaphase transition | 3 | $1.30 \times 10^{-3}$ | $4.74 \times 10^{-2}$ |
| KEGG pathway  | hsa04110:Cell cycle            | 13    | $3.42 \times 10^{-14}$ | $2.77 \times 10^{-12}$ |
|               | hsa04114:Oocyte meiosis        | 7     | $1.35 \times 10^{-7}$ | $1.09 \times 10^{-5}$ |
|               | hsa04914:Progesterone-mediated oocyte maturation | 6 | $3.97 \times 10^{-7}$ | $3.22 \times 10^{-5}$ |
|               | hsa04155:p53 signaling pathway | 3     | $9.78 \times 10^{-5}$ | $7.92 \times 10^{-3}$ |
|               | hsa04068:FoxO signaling pathway | 3 | $2.96 \times 10^{-4}$ | $2.40 \times 10^{-2}$ |
|               | hsa05202:Transcriptional misregulation in cancer | 3 | $4.02 \times 10^{-4}$ | $3.26 \times 10^{-2}$ |
|               | hsa04974:Protein digestion and absorption | 2 | $5.71 \times 10^{-4}$ | $4.62 \times 10^{-2}$ |
clinical factor (Table 3). Consequently, the samples were divided into early (stage 1–2) and advanced (stage 3–4). The K–M curve revealed that patients in the early group had a significantly better prognosis than those in the advanced group (Figure 4a).

In addition, the expression of 17 DERs between patients in the early and advanced groups was also analyzed. The results indicated that 12 of these DERs exhibited a significantly higher expression level in the advanced group than in the early group (p < 0.05) – including LINC00665, chromobox 2 (CBX2), cyclin A2 (CCNA2), cyclin B1 (CCNB1), centromere protein F (CENPF), FLVCR heme transporter 1 (FLVCR1), Fraser extracellular matrix complex subunit 1 (FRAS1), kinesin family member 20A (KIF20A), recQ like helicase 4 (RECQL4), solute carrier family 7 member 6 (SLC7A6), SPC24 component of NDC80 kinetochore complex (SPC24), and ZW10 interacting kinetochore protein (ZWINT; Figure 4b). The Sankey diagram revealed that LINC00665

![Figure 3: The K–M curve of the lncRNAs and mRNAs that are significantly correlated with independent prognosis.](image)

### Table 3: Univariate and multivariate Cox regression analysis identified independent prognostic clinical factor

| Clinical characteristics       | Univariate Cox | Multivariate Cox |
|-------------------------------|----------------|------------------|
|                               | HR (95% CI)    | p value          | HR (95% CI)    | p value    |
| Age (years, mean ± SD)        | 1.012 (0.998–1.026) | 4.790 × 10⁻² | 1.011 (0.997–1.026) | 1.270 × 10⁻¹ |
| Gender (men/women)            | 0.817 (0.573–1.164) | 2.618 × 10⁻¹ | —              | —          |
| Pathologic M (M0/M1/–)        | 4.032 (0.763–12.83) | 1.057 × 10⁻¹ | —              | —          |
| Pathologic N (N0/N1/–)        | 2.004 (0.691–8.181) | 3.327 × 10⁻¹ | —              | —          |
| Pathologic T (T1/T2/T3/T4/–)  | 1.675 (0.916–2.007) | 1.017 × 10⁻¹ | —              | —          |
| Pathologic stage (I/II/III/IV/–)| 1.661 (1.355–2.037) | 1.034 × 10⁻⁶ | 1.668 (1.359–2.045) | 9.240 × 10⁻⁷ |
| Histologic grade (G1/G2/G3/G4) | 1.121 (0.887–1.416) | 3.392 × 10⁻¹ | —              | —          |
| Vascular invasion (Yes/No/–)  | 1.351 (0.892–2.047) | 1.537 × 10⁻¹ | —              | —          |
| Recurrence (Yes/No/–)         | 1.375 (0.914–2.068) | 1.249 × 10⁻¹ | —              | —          |
was modified by the m6A enzymes IGF2BP1, IGF2BP2, and YTHDF1. Moreover, these three m6A enzymes regulated the methylation of the 11 mRNAs (Figure 4c).

Furthermore, based on the m6A2Target database, we counted the evidence for binding 11 mRNAs, one lncRNA, and three m6A enzymes involved in Figure 4c (Table S2). The results revealed that in the Huh-7 cell line, once IGF2BP1 was knocked down, the expression levels of LINC00665 and ZWINT will be upregulated and downregulated, respectively. In addition, several studies have confirmed a direct interaction between the m6A enzyme and mRNA using eCLIP-seq.

### 3.5 Verification of the expression of DERs

To analyze the expression of 12 DERs between tumor samples and normal samples, the expression values of these 12 DERs were extracted from the TCGA database. The
results indicated that these 12 DERs exhibited a significantly higher expression in the tumor samples than in the normal samples ($p < 0.001$; Figure 5a). GSE55092 was used to validate the expression of 10 mRNAs. The results revealed that, except for LINC00665 and FRAS1, all the other mRNAs exhibited significantly higher expression in tumor samples than in normal samples ($p < 0.001$; Figure 5b).

4 Discussion

To understand how lncRNAs play a role in HCC by regulating mRNA expression via the modulation of m6A enzymes, 85 and 747 DElncRNAs and DEmRNAs were screened, respectively. A comprehensive network containing m6A proteins, lncRNAs, and mRNAs was constructed. The mRNAs included in this network were primarily involved in the mitotic division, cell cycle checkpoints, and the p53 signaling pathway. It is well established that mitotic cell division is a series of processes designed to accurately propagate the genomic material from a maternal cell into two daughter cells. This process is important for protecting genome integrity [21]. Studies have reported that any disorder in the process of cell division may lead to malignancy [22]. The p53 tumor suppressor gene mutated in more than half of all human malignancies plays a critical role in regulating the cell cycle, cell senescence, and apoptosis and maintaining genomic stability [23]. In addition, there are several reports on the role of p53 in HCC [24].

Following the prognostic and Cox regression analyses, 3 IncRNAs and 14 mRNAs were identified as independent prognostic RNAs. Low expression of these 17 RNAs in TCGA samples was significantly associated with a better prognosis. The samples were further divided into early and advanced stages according to the independent prognostic clinical factor of the pathologic stage, following which 12 RNAs (1 IncRNA and 11 mRNAs) were screened and observed to be expressed significantly differently in various groups. LINC00665 plays a role in cancer development. An earlier study has reported that LINC00665 may be involved in HCC cell cycle regulation, and the high expression of LINC00665 in HCC patients is significantly associated with poor prognosis [25]. This finding is consistent with our observations. Further in vitro experiments confirmed that the depletion of LINC00665 inhibits HCC cell viability and induces cell apoptosis as well as autophagy [26]. However, there have been no studies related to LINC00665 and m6A.

Based on our hypothesis, LINC00665 could regulate 11 mRNAs by modulating the m6A enzymes IGF2BP1, IGF2BP2, and YTHDF1. In lung adenocarcinoma tissues, the expression of LINC00665 is closely related to the aggressive clinicopathological characteristics of patients and can be used as an independent predictor of relapse-free survival [27]. CIP2A-BP is a micropeptide encoded by LINC00665, and its expression in breast cancer cell lines can be downregulated by TGF-b. In breast cancer, downregulated CIP2A-BP expression is associated with tumor metastasis and poor overall survival [28]. It has been earlier reported that LINC00665 can also regulate the occurrence and development of HCC by regulating the expression of cell cycle-related genes CCNA2 and CCNB1 [25]. Further research is necessary to verify whether LINC00665 affects the expression of CCNA2 and CCNB1 via the m6A enzyme. The protein encoded by CCNA2 is a cell cycle regulator [29]. CCNA2 has been proven to be a target of miRNAs that regulate the proliferation of HCC cells [30]. Moreover, as a key promoter of mitosis control, the role of CCNB1 in HCC has also been widely reported. The high

![Figure 5: The relative expression levels of 12 RNAs in (a) TCGA and (b) GSE55092 database between tumor and control samples.](image)
expression of CCNB1 is usually closely related to the poor prognosis of HCC patients [31,32]. In this study, the expression of CCNB1 in patients with advanced-stage HCC was significantly higher than that in patients with early stage. It has been reported that CBX2 could regulate proliferation and apoptosis via the phosphorylation of YAP in HCC [33]. High expression of FLVCR1 was significantly associated with poor prognostic value in HCC patients [34]. CCNB1 was identified as a potential prognostic biomarker and target for HCC [35]. It is reported that upregulated RECQL4 [36], SPC24 [37], and KIF20A [38] could predict poor prognosis in HCC, whereas upregulated ZWINT was associated with great prognosis in patients with HCC after surgery [39].

m6A2Target database (http://m6a2target.canceromics.org) is the most comprehensive database of target genes corresponding to the three types of m6A enzymes (writers, erasers, and readers) so far. In this database, the validated targets module contains experimentally verified relationship pairs between m6A enzymes and target genes, whereas the Potential Targets module stores the relationship pairs between m6A enzymes and target genes obtained through high-throughput sequencing data analysis. Several studies have confirmed that there was a direct interaction between the m6A enzyme and mRNA using eCLIP-seq [40,41]. However, these results supported by experimental evidence in the database do not include relevant research on HCC. Therefore, further experimental verification is necessary for the correlation between m6A enzyme and target gene in HCC. In conclusion, this study speculated that LINCO00665 plays a role in HCC by regulating the above 11 mRNAs via modulation of IGF2BP1, IGF2BP2, and YTHDF1. In so doing, it provided new insights into the roles of IncRNA and m6A enzymes in HCC. Further determination of the regulatory relationship requires more diverse in vivo and in vitro experiments in the future.

Funding information: Authors state no funding involved.

Author contributions: M.L. and X.D. conceived and designed the project. X.L. and F.W. collected the data. M.L. and X.D. performed the interpretation of data. L.G. and F.G. performed the statistical analysis. M.L. and X.D. wrote the manuscript. L.G. and F.G. revised the article. All authors read and approved the final manuscript.

Conflict of interest: Authors state no conflict of interest.

Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Zhu XM, Pan HM, Liu LL. Long non-coding RNA network: novel insight into hepatocellular carcinoma metastasis (Review). Int J Mol Med. 2021;48(1):12.

[2] Bai S, Yang P, Xie Z, Li J, Lei Z, Xia Y, et al. Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radio-frequency ablation for early Hepatitis B virus-related hepatocellular carcinoma. Ann Surgical Oncol. 2021;28:1–12.

[3] Kurebayashi Y, Kubota N, Sakamoto M. Immune microenvironment of hepatocellular carcinoma, intrahepatic cholangiocarcinoma and liver metastasis of colorectal adenocarcinoma: Relationship with histopathological and molecular classifications. Hepatol Res. 2021;51(1):5–18.

[4] Lee Y-T, Wang JJ, Luu M, Noureddin M, Kosari K, Agopian VG, et al. The mortality and overall survival trends of primary liver cancer in the United States. JNCI: J Natl Cancer Inst. 2021;113:1531–41.

[5] Xia YX, Zhang F, Li XC, Kong LB, Zhang H, Li DH, et al. Surgical treatment of primary liver cancer: a report of 10,966 cases. Zhonghua wai ke za zhi (Chin J Surg). 2021;59(1):6–17.

[6] Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed Pharma. 2019;112:108613.

[7] Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m6A (6A) decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28(6):516–24.

[8] Panneerdoss S, Eedunuri VK, Yadav P, Timilsina S, Rajamanickam S, Viswanadhapalli S, et al. Cross-talk among writers, readers, and erasers of m(6)A regulates cancer growth and progression. eaar8263. 2018;4(10):8263.

[9] Dixit D, Prager BC, Gimple RC, Poh HX, Wang Y, Wu Q, et al. The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells. Cancer discovery. 2021;11(2):480–99.

[10] Tzelepis K, De Braekeleer E, Yankova E, Rak J, Aspris D, Domingues AF, et al. Pharmacological inhibition of the RNA m6A writer METTL3 as a novel therapeutic strategy for acute myeloid leukemia. DC. American Society of Hematology Washington; 2019.

[11] Liu H, Xu Y, Yao B, Sui T, Lai L, Li Z. A novel N6-methyladenosine (m6A)-dependent fate decision for the IncRNA THOR. Cell Death Dis. 2020;11(8):613.

[12] Wang J, Su Z, Lu S, Fu W, Liu Z, Jiang X, et al. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer. Cлин Chim Acta; Int J Clin Chem. 2018;485:229–33.

[13] Wang Y, Yang L, Chen T, Liu X, Guo Y, Zhu Q, et al. A novel IncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting mir-194-5p/FOXA1 axis. Mol Cancer. 2019;18(1):28.

[14] Wen D, Zou W, Wen X, Yang Y, Chen Y, He Y, et al. Urban-rural disparity in colorectal cancer incidence and increasing trend in relation to socioeconomic development and urbanization in China. J Int Med Res. 2018;46(10):4181–96.

[15] Ritchie ME, Shipson B, Wu D, Hu Y, Law CW, Shi W, et al. llimma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.

[16] Wang L, Cao C, Ma Q, Zeng Q, Wang H, Cheng Z, et al. RNA-seq analyses of multiple meristems of soybean: novel and
alternative transcripts, evolutionary and functional implications. BMC Plant Biol. 2014;14:169.

[17] Deng S, Zhang H, Zhu K, Li X, Ye Y, Li R, et al. M6A2Target: a comprehensive database for targets of m6A writers, erasers and readers. Brief Bioinforma. 2021;22(3):bbaa055.

[18] Consortium GO. The gene ontology resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47(D1):D330–8.

[19] Kanehisa M, Furumichi M, Sato Y, Ishitobi-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–51.

[20] Wang P, Wang Y, Hang B, Zou X, Mao JH. A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget. 2016;7(34):55343–51.

[21] Petsalaki E, Zachos G. DNA damage response proteins regulating mitotic cell division: double agents preserving genome stability. FEBS J. 2020;287(9):1700–21.

[22] Chen C, Chen S, Pang L, Yan H, Luo M, Zhao Q. Analysis of the expression of cell division cycle-associated genes and its prognostic significance in human lung carcinoma: a review of the literature databases. BioMed Res Int. 2020;2020:6412593.

[23] Zhang H, Zhang X, Li X, Meng WB, Bai ZT, Rui SZ, et al. Effect of CCNB1 silencing on cell cycle, senescence, and apoptosis through the p53 signaling pathway in pancreatic cancer. J Cell Physiol. 2018;234(1):619–31.

[24] Qin G, Tu X, Li H, Cao P, Chen X, Song J, et al. Long noncoding RNA p53-stabilizing and activating RNA promotes p53 signaling by inhibiting heterogeneous nuclear ribonucleoprotein K desumoylation and suppresses hepatocellular carcinoma. Hepatol (Baltimore, Md). 2020;71(1):112–29.

[25] Wen DY, Lin P, Pang YY, Chen G, He Y, Dang YW, et al. Expression of the long intergenic non-protein coding RNA 665 (LINC00665) gene and the cell cycle in hepatocellular carcinoma using the cancer genome atlas, the gene expression omnibus, and quantitative real-time polymerase chain reaction. Med Sci Monitor. Int Med J Exp Clin Res. 2018;24:2786–808.

[26] Shan Y, Li P. Long intergenic non-protein coding RNA 665 regulates viability, apoptosis, and autophagy via the MRIR-186-5p/MAP4K3 Axis in hepatocellular carcinoma. Yonsei Med J. 2019;60(9):842–53.

[27] Cong Z, Diao Y, Xu Y, Li X, Jiang Z, Shao C, et al. Long noncoding RNA linc00665 promotes lung adenocarcinoma progression and functions as ceRNA to regulate AKR1B10-ERK signaling by sponging miR-9B. Cell Death Dis. 2019;10(2):1–15.

[28] Guo B, Wu S, Zhu X, Zhang L, Deng J, Li F, et al. Micropeptide CIP2A-BP encoded by LINC 00665 inhibits triple-negative breast cancer progression. EMBO J. 2020;39(1):e102190.

[29] Nault JC, Datta S, Imbeaud S, Franchi A, Mallet M, Couchy G, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015;47(10):1187–93.

[30] Yang F, Gong J, Wang G, Chen P, Yang L, Wang Z. Waltonitine inhibits proliferation of hepatoma cells and tumorigenesis via FXR-miR-22-CCNA2 signaling pathway. Oncotarget. 2016;7(46):75165–75.

[31] Gu J, Liu X, Li J, He Y. MicroRNA-144 inhibits cell proliferation, migration and invasion in human hepatocellular carcinoma by targeting CCNB1. Cancer Cell Int. 2019;19:15.

[32] Zou Y, Ruan S, Jin L, Chen Z, Han H, Zhang Y, et al. CDK1, CCNB1, and CCNB2 are Prognostic Biomarkers and Correlated with Immune Infiltration in Hepatocellular Carcinoma. Med Sci Monitor: Int Med J Exp Clin Res. 2020;26:e925289.

[33] Mao J, Tian Y, Wang C, Jiang K, Li R, Yao Y, et al. CBX2 regulates proliferation and apoptosis via the phosphorylation of YAP in hepatocellular carcinoma. J Cancer. 2019;10(12):2706–19.

[34] Chen J, Chuan H, Pan R, Du X, Fu H, Shan Y. Identification of Iron metabolism-related genes signature and novel role of FLVCR1 in hepatocellular carcinoma; 2020. doi: 10.21203/rs.3.rs-45663/v1.

[35] Huang Y, Chen X, Wang L, Wang T, Tang X, Su X. Centromere protein F (CENPF) serves as a potential prognostic biomarker and target for human hepatocellular carcinoma. J Cancer. 2021;12(10):2933–51.

[36] Li J, Jin J, Liao M, Deng W, Chen X, Wu Y, et al. Upregulation of RECLQ4 expression predicts poor prognosis in hepatocellular carcinoma. Oncol Lett. 2018;15(4):4248–54.

[37] Wang Y, Yang H, Zhang G, Luo C, Zhang S, Luo R, et al. hsa-miR-7-5p suppresses proliferation, migration and promotes apoptosis in hepatocellular carcinoma cell lines by inhibiting SPC24 expression. Biochem Biophys Res Commun. 2021;561:80–7.

[38] Wu C, Qi X, Qiu Z, Deng G, Zhong L. Low expression of KIF20A suppresses cell proliferation, promotes chemosensitivity and is associated with better prognosis in HCC. Aging (Albany NY). 2021;13(18):22148–63.

[39] Yang X-Y, Wu B, Ma S-L, Yin L, Wu M-C, Li A-J. Decreased expression of ZWINT is associated with poor prognosis in patients with HCC after surgery. Technol Cancer Res Treat. 2018;17:553033818794190.

[40] Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N(6)-methyladenosine by IFG2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285–95.

[41] Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Gutman M, et al. m(6)A RNA methylation promotes XIIS-mediated transcriptional repression. Nature. 2016;537(7620):369–73.